

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 June 2002 (27.06.2002)

PCT

(10) International Publication Number
WO 02/50032 A1

(51) International Patent Classification⁷: C07D 209/64,
209/66, 413/12, 405/12, 409/12, 401/12, 417/12, A61K
31/4035

(21) International Application Number: PCT/GB01/05676

(22) International Filing Date:
20 December 2001 (20.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0031302.3 21 December 2000 (21.12.2000) GB

(71) Applicant (for all designated States except US): GLAXO
GROUP LIMITED [GB/GB]; Glaxo Wellcome House,
Berkeley Avenue, Greenlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GIBLIN, Gerard,
Martin, Paul [GB/GB]; GlaxoSmithKline, The Frythe,
Welwyn, Hertfordshire AL6 9AR (GB). JONES, Haydn,
Terence [GB/GB]; GlaxoSmithKline, Gunnels Wood
Road, Stevenage, Hertfordshire SG1 2NY (GB). MA-
SON, Andrew, McMurtrie [GB/GB]; GlaxoSmithKline,
Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY
(GB). MILLER, Neil, Derek [GB/GB]; GlaxoSmithK-
line, Gunnels Wood Road, Stevenage, Hertfordshire SG1
2NY (GB). ROOMANS, Susan [GB/GB]; GlaxoSmithK-
line, Gunnels Wood Road, Stevenage, Hertfordshire SG1

2NY (GB). SHANAHAN, Stephen, Edward [GB/GB];
GlaxoSmithKline, Gunnels Wood Road, Stevenage,
Hertfordshire SG1 2NY (GB). WALKER, Ann, Louise
[GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Steve-
nage, Hertfordshire SG1 2NY (GB).

(74) Agent: GIDDINGS, Peter, John; Corporate Intellectual
Property, GlaxoSmithKline, 980 Great West Road, Brent-
ford, Middlesex TW8 9GS (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NAPHTHALENE DERIVATIVES WHICH BIND TO THE EP4 RECEPTOR




(57) Abstract: Compounds of formula (I) and pharmaceutically acceptable derivatives thereof bind with high affinity to the EP4 receptor and are of use in the treatment or prevention of conditions such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

NAPHTHALENE DERIVATIVES WHICH BIND TO THE EP4 RECEPTOR

This invention relates to naphthalene derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.

The EP4 receptor is a 7-transmembrane receptor and its natural ligand is the prostaglandin PGE₂. PGE₂ also has affinity for the other EP receptors (types EP1, EP2 and EP3). The EP4 receptor is associated with smooth muscle relaxation, inflammation, lymphocyte differentiation, bone metabolism processes, allergic activities, promotion of sleep, renal regulation and gastric or enteric mucus secretion. We have now found a novel group of compounds which bind with high affinity to the EP4 receptor.

The invention thus provides compounds of the formula (I)



(I)

and pharmaceutically acceptable derivatives thereof in which:

a = 0 or 1;

b = 0 to 3;

20 R¹ is H, halogen, C₁₋₆alkyl, S-C₁₋₆alkyl, C₁₋₆alkoxy, OCF₃, OCH₂CF₃, O-cyclopropyl, OCH₂-cyclopropyl, NH₂, NHC₁₋₆alkyl, N(C₁₋₆alkyl)₂, NO₂, OH, CH₂OC₁₋₆alkyl or CH₂OH;

each R² is independently selected from C₁₋₄alkyl;

R³ is H or O;

25 R⁴ is H or C₁₋₆alkyl;

R⁵ and R⁶ are each independently selected from H, halogen, C₁₋₃alkyl, or are taken together to form a cyclopropyl ring;

- R^7 to R^{10} are each independently selected from H, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxy substituted by one or more fluorine atoms, O-cyclopropyl, OCH_2 -cyclopropyl, S- C_{1-6} alkyl, NH_2 , NHC_{1-6} alkyl, $N(C_{1-6}alkyl)_2$, halogen, NO_2 , OH, $CH_2OC_{1-6}alkyl$, CH_2OH ;
- 5 R^{11} is selected from H, OH, halogen, dihalogen, NH_2 , $NHC_{1-6}alkyl$, $N(C_{1-6}alkyl)_2$, $C_{1-6}alkyl$, $C_{1-6}dialkyl$, $C_{1-6}alkoxy$, $NHCO(C_{1-6}alkyl)$, or $=O$;
- R^{12} is selected from H, $C_{1-6}alkyl$, phenyl, phenyl substituted by one or more R^{13} , phenyl fused to a heterocycle, naphthyl, naphthyl substituted by one or more R^{13} , $C_{4-7}cycloalkyl$, $C_{4-7}cycloalkyl$ fused to a benzene ring, $OCOC_{1-6}alkyl$, heteroaryl or heteroaryl substituted by one or more R^{13} ;
- 10 R^{13} is halogen, $C_{1-6}alkyl$, $C_{1-6}alkyl$ substituted by one or more fluorine atoms, $C_{1-6}alkoxy$, $C_{1-6}alkoxy$ substituted by one or more fluorine atoms, phenyl, CN, CO_2H , $CO_2C_{1-6}alkyl$, OH, NH_2 , $NHC_{1-6}alkyl$, $N(C_{1-6}alkyl)_2$, $S(O)_n C_{1-6}alkyl$ where n is 0, 1 or 2, $SO_2N(C_{1-6}alkyl)_2$, $CONH_2$, $CONHC_{1-6}alkyl$, $CON(C_{1-6}alkyl)_2$, $COC_{1-6}alkyl$, benzyloxy, CH_2CO_2H , $CH_2CO_2C_{1-6}alkyl$, NO_2 or $NHCO(C_{1-6}alkyl)$;
- 15 ---- is a single bond or, when R^3 is O, a double bond.

By pharmaceutically acceptable derivative is meant any pharmaceutically acceptable salt or solvate of the compounds of formula (I), or any other compound which upon administration to the recipient is capable of providing

20 (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.

It will be appreciated by those skilled in the art that the compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at

25 any of the functional groups in the compounds, and that the compounds of formula (I) may be derivatised at more than one position.

It will be appreciated that, for pharmaceutical use, the salts referred to above will be physiologically acceptable salts, but other salts may find use, for example in

30 the preparation of compounds of formula (I) and the physiological acceptable salts thereof.

Pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse, *J. Pharm. Sci.*, 1977, 66, 1-19. Suitable pharmaceutically acceptable salts include: acid addition salts formed with inorganic acids or organic acids, preferably inorganic acids e.g. hydrochlorides, hydrobromides, sulphates and acetates; and alkali metal salts, formed from the addition of alkali metal bases, such as alkali metal hydroxides e.g. sodium salts. Further representative examples of pharmaceutically acceptable salts include those formed from maleic, fumaric, benzoic, ascorbic, pantoic, succinic, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, cyclohexylsulfamic, phosphoric and nitric acids.

The term 'halogen' is used to represent fluorine, chlorine, bromine or iodine.

The term 'alkyl' as a group or part of a group means a straight or branched chain alkyl group, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl or t-butyl group.

The term 'alkoxy' as a group or as part of a group means a straight or branched chain alkyl group having an oxygen atom attached to the chain, for example a methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy or t-butoxy group.

The term 'heterocycle' as a group or as part of a group means a non-aromatic five or six membered ring which contains from 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur and which may be optionally substituted with one or more C₁₋₆alkyl groups. Examples of suitable heterocycles include 1,4-dioxane, 1,3-dioxolane and 2,2-dimethyl-1,3-dioxolane.

The term 'heteroaryl' as a group or as part of a group means a monocyclic five or six membered aromatic ring, or a fused bicyclic aromatic ring system comprising two of such monocyclic five or six membered aromatic rings. These heteroaryl rings contain one or more heteroatoms selected from nitrogen, oxygen or sulfur, where N-oxides, sulfur oxides and sulfur dioxides are permissible heteroatom substitutions. Examples of "heteroaryl" used herein

include furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyrimidine, quinoline, isoquinoline, benzofuran, benzothiophene, indole, and indazole.

5

In one aspect of the invention $a = 1$.

In another aspect of the invention $b = 1$.

10 In another aspect of the invention R^1 is at the 6-position of the naphthalene ring, as defined in formula (I).

In another aspect of the invention R^1 is H or halogen.

15 In another aspect of the invention R^1 is H or bromine.

In another aspect of the invention each R^2 is ethyl.

In another aspect of the invention R^4 is H or methyl.

20

In another aspect of the invention R^5 and R^6 are each independently selected from H, chlorine, methyl or ethyl, or are taken together to form a cyclopropyl ring.

In another aspect of the invention each of R^7 to R^{11} is hydrogen.

25

In another aspect of the invention R^{12} is selected from C_{1-6} alkyl (preferably methyl), phenyl, phenyl substituted by one or more R^{13} , phenyl fused to a heterocycle selected from 1,4-dioxane, 1,3-dioxolane and 2,2-dimethyl-1,3-dioxolane, naphthyl, naphthyl substituted by one or more C_{1-6} alkoxy (preferably methoxy), thiophene, thiazole, thiazole substituted by one or more C_{1-6} alkyl (preferably methyl), indole, indole substituted by one or more C_{1-6} alkyl (preferably methyl), or benzofuran.

30

In another aspect of the invention R^{13} is halogen, C_{1-6} alkyl, C_{1-6} alkyl substituted by one or more fluorine atoms, C_{1-6} alkoxy, C_{1-6} alkoxy substituted by one or more

35

fluorine atoms, phenyl, CN, CO₂C₁₋₆alkyl, OH, N(C₁₋₆alkyl)₂, SO₂N(C₁₋₆alkyl)₂, benzyloxy, CH₂CO₂H, CH₂CO₂C₁₋₆alkyl or NO₂.

5 In another aspect of the invention R¹³ is chlorine, fluorine, methyl, ethyl, i-propyl, i-butyl, CF₃, methoxy, ethoxy, OCF₃, phenyl, CN, CO₂CH₃, OH, NMe₂, SO₂NMe₂, benzyloxy, CH₂CO₂H, CH₂CO₂Me or NO₂.

10 In another aspect of the invention R¹² is phenyl substituted by one or two groups selected from chlorine (preferably as a substituent in the 2 or 4 position of the phenyl ring), fluorine (preferably as a substituent in the 2, 3, 4, or 2 and 5 positions of the phenyl ring), methyl (preferably as a substituent in the 2, 3 or 4 position of the phenyl ring, or, if two substituents are present, in the 2 and 5, or 2 and 6 positions of the phenyl ring), ethyl (preferably as a substituent in the 4 position of the phenyl ring), i-propyl (preferably as a substituent in the 4 position of the phenyl ring), i-butyl (preferably as a substituent in the 4 position of the phenyl ring), methoxy (preferably as a substituent in the 2, 3 or 4 position of the phenyl ring, or, if two substituents are present, in the 2 and 3, 3 and 4, 2 and 5, or 3 and 5 positions of the phenyl ring), ethoxy (preferably as a disubstituent in the 3 and 4 positions of the phenyl ring), OCF₃ (preferably as a substituent in the 3 or 4 position of the phenyl ring), phenyl (preferably as a substituent in the 4 position of the phenyl ring), benzyloxy (preferably as a substituent in the 3 position of the phenyl ring), or CH₂CO₂Me (preferably as a substituent in the 2 position of the phenyl ring).

25 In another aspect of the invention R¹² is phenyl substituted by one or two groups selected from methyl (preferably substituted in the 4 position of the phenyl ring) or methoxy (preferably substituted in the 2, 3 or 4 position of the phenyl ring, or, if two substituents are present, in the 2 and 3 or 3 and 4 positions of the phenyl ring).

30

It is to be understood that the present invention covers all combinations of particular aspects of the invention as described hereinabove.

35 In a particular aspect of the invention there is provided a group of compounds of formula (I) (group A) wherein: a is 1, b is 1, R¹ is H or bromine; each R² is ethyl;

R^3 is H; R^4 is H or methyl; R^5 and R^6 are each independently selected from H, halogen, C_{1-3} alkyl, or are taken together to form a cyclopropyl ring; each of R^7 to R^{11} is hydrogen; R^{12} is selected from H, C_{1-6} alkyl, phenyl, phenyl substituted by one or more R^{13} , phenyl fused to a heterocycle, naphthyl, naphthyl substituted by one or more R^{13} , C_{4-7} cycloalkyl, C_{4-7} cycloalkyl fused to a benzene ring, OCOC $_{1-6}$ alkyl, heteroaryl or heteroaryl substituted by one or more R^{13} ; R^{13} is halogen, C_{1-6} alkyl, C_{1-6} alkyl substituted by one or more fluorine atoms, C_{1-6} alkoxy, C_{1-6} alkoxy substituted by one or more fluorine atoms, phenyl, CN, CO₂H, CO₂ C_{1-6} alkyl, OH, NH₂, NHC $_{1-6}$ alkyl, N(C_{1-6} alkyl)₂, S(O)_n C_{1-6} alkyl where n is 0, 1 or 2, SO₂N(C_{1-6} alkyl)₂, CONH₂, CONHC $_{1-6}$ alkyl, CON(C_{1-6} alkyl)₂, COC $_{1-6}$ alkyl, benzyloxy, CH₂CO₂H, CH₂CO₂ C_{1-6} alkyl, NO₂ or NHCO(C_{1-6} alkyl).

Within group A, there is provided a further group of compounds (group A1) wherein: R^1 is H; each R^2 is ethyl; R^3 is H; R^4 is H; R^5 and R^6 are each independently selected from H, chlorine, methyl or ethyl, or are taken together to form a cyclopropyl ring; each of R^7 to R^{11} is hydrogen; R^{12} is selected from phenyl, phenyl substituted by one or more R^{13} , phenyl fused to a heterocycle, naphthyl, naphthyl substituted by one or more C_{1-6} alkoxy, heteroaryl or heteroaryl substituted by one or more C_{1-6} alkyl; R^{13} is halogen, C_{1-6} alkyl, C_{1-6} alkyl substituted by one or more fluorine atoms, C_{1-6} alkoxy, C_{1-6} alkoxy substituted by one or more fluorine atoms, phenyl, CN, CO₂H, CO₂ C_{1-6} alkyl, OH, NH₂, NHC $_{1-6}$ alkyl, N(C_{1-6} alkyl)₂, S(O)_n C_{1-6} alkyl where n is 0, 1 or 2, SO₂N(C_{1-6} alkyl)₂, CONH₂, CONHC $_{1-6}$ alkyl, CON(C_{1-6} alkyl)₂, COC $_{1-6}$ alkyl, benzyloxy, CH₂CO₂H, CH₂CO₂ C_{1-6} alkyl, NO₂ or NHCO(C_{1-6} alkyl).

Within group A there is provided a further group of compounds wherein R^1 is at the 6-position of the naphthalene ring, as defined in formula (I).

In a particular aspect of the invention there is provided a group of compounds of formula (I) (group B) wherein: a is 1, b is 1, R^1 is H or bromine; each R^2 is ethyl; R^3 is O; R^4 is H or methyl; R^5 and R^6 are each independently selected from H, halogen, C_{1-3} alkyl, or are taken together to form a cyclopropyl ring; each of R^7 to R^{11} is hydrogen; R^{12} is selected from H, C_{1-6} alkyl, phenyl, phenyl substituted by one or more R^{13} , phenyl fused to a heterocycle, naphthyl, naphthyl substituted by one or more R^{13} , C_{4-7} cycloalkyl, C_{4-7} cycloalkyl fused to a benzene ring,

OCOC₁₋₆alkyl, heteroaryl or heteroaryl substituted by one or more R¹³; R¹³ is halogen, C₁₋₆alkyl, C₁₋₆alkyl substituted by one or more fluorine atoms, C₁₋₆alkoxy, C₁₋₆alkoxy substituted by one or more fluorine atoms, phenyl, CN, CO₂H, CO₂C₁₋₆alkyl, OH, NH₂, NHC₁₋₆alkyl, N(C₁₋₆alkyl)₂, S(O)_nC₁₋₆alkyl where n is 0, 1 or 2, SO₂N(C₁₋₆alkyl)₂, CONH₂, CONHC₁₋₆alkyl, CON(C₁₋₆alkyl)₂, COC₁₋₆alkyl, benzyloxy, CH₂CO₂H, CH₂CO₂C₁₋₆alkyl, NO₂ or NHCO(C₁₋₆alkyl).

Within group B, there is provided a further group of compounds (group B1) wherein: R¹ is H; each R² is ethyl; R³ is O; R⁴ is H; R⁵ and R⁶ are each independently selected from H, chlorine, methyl or ethyl, or are taken together to form a cyclopropyl ring; each of R⁷ to R¹¹ is hydrogen; R¹² is selected from phenyl, phenyl substituted by one or more R¹³, phenyl fused to a heterocycle, naphthyl, naphthyl substituted by one or more C₁₋₆alkoxy, heteroaryl or heteroaryl substituted by one or more C₁₋₆alkyl; R¹³ is halogen, C₁₋₆alkyl, C₁₋₆alkyl substituted by one or more fluorine atoms, C₁₋₆alkoxy, C₁₋₆alkoxy substituted by one or more fluorine atoms, phenyl, CN, CO₂H, CO₂C₁₋₆alkyl, OH, NH₂, NHC₁₋₆alkyl, N(C₁₋₆alkyl)₂, S(O)_nC₁₋₆alkyl where n is 0, 1 or 2, SO₂N(C₁₋₆alkyl)₂, CONH₂, CONHC₁₋₆alkyl, CON(C₁₋₆alkyl)₂, COC₁₋₆alkyl, benzyloxy, CH₂CO₂H, CH₂CO₂C₁₋₆alkyl, NO₂ or NHCO(C₁₋₆alkyl).

Within group B there is provided a further group of compounds wherein R¹ is at the 6-position of the naphthalene ring, as defined in formula (I).

It is to be understood that the present invention encompasses all isomers of formula (I) and their pharmaceutically acceptable derivatives, including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures).

In one aspect the invention provides the following compounds and pharmaceutically acceptable derivatives thereof:

1-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]-N-[(4-methoxyphenyl)acetyl]methanesulfonamide,

1-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]-N-[(2-methoxyphenyl)acetyl]methanesulfonamide,

1-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]-N-[(2,3-

dimethoxyphenyl)acetyl]methanesulfonamide,
1-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]-N-[(3,4-
dimethoxyphenyl)acetyl]methanesulfonamide,
1-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]-N-[(3-
methoxyphenyl)acetyl]methanesulfonamide,
1-[4-(4,9-diethoxy-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]-N-[(3,4-
dimethoxyphenyl)acetyl]methanesulfonamide,
1-[4-(4,9-diethoxy-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]-N-[(4-
methylphenyl)acetyl]methanesulfonamide, and
1-[4-(4,9-diethoxy-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]-N-[(2-
methoxyphenyl)acetyl]methanesulfonamide.

Since the compounds of the present invention, in particular compounds of
formula (I), are intended for use in pharmaceutical compositions, it will be
understood that they are each provided in substantially pure form, for example at
5 least 50% pure, more suitably at least 75% pure and preferably at least 95%
pure (% are on a wt/wt basis). Impure preparations of the compounds of formula
(I) may be used for preparing the more pure forms used in the pharmaceutical
compositions. Although the purity of intermediate compounds of the present
invention is less critical, it will be readily understood that the substantially pure
10 form is preferred as for the compounds of formula (I). Preferably, whenever
possible, the compounds of the present invention are obtained in crystalline
form.

When some of the compounds of this invention are allowed to crystallise or are
15 recrystallised from organic solvents, solvent of crystallisation may be present in
the crystalline product. This invention includes within its scope such solvates.
Similarly, some of the compounds of this invention may be crystallised or
recrystallised from solvents containing water. In such cases water of hydration
may be formed. This invention includes within its scope stoichiometric hydrates
20 as well as compounds containing variable amounts of water that may be
produced by processes such as lyophilisation. In addition, different
crystallisation conditions may lead to the formation of different polymorphic
forms of crystalline products. This invention includes within its scope all
polymorphic forms of the compounds of formula (I).

The compounds of the invention bind to the EP4 receptor and are therefore useful in treating EP4 receptor mediated diseases.

5 In view of their ability to bind to the EP4 receptor, the compounds of the invention are useful in the treatment of the disorders that follow. Thus, the compounds of formula (I) are useful as analgesics. For example they are useful in the treatment of chronic articular pain (e.g. rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis) including the
10 property of disease modification and joint structure preservation; musculoskeletal pain; lower back and neck pain; sprains and strains; neuropathic pain; sympathetically maintained pain; myositis; pain associated with cancer and fibromyalgia; pain associated with migraine; pain associated with influenza or other viral infections, such as the common cold; rheumatic fever; pain associated
15 with functional bowel disorders such as non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome; pain associated with myocardial ischemia; post operative pain; headache; toothache; and dysmenorrhea.

20 The compounds of the invention are particularly useful in the treatment of neuropathic pain. Neuropathic pain syndromes can develop following neuronal injury and the resulting pain may persist for months or years, even after the original injury has healed. Neuronal injury may occur in the peripheral nerves, dorsal roots, spinal cord or certain regions in the brain. Neuropathic pain syndromes are traditionally classified according to the disease or event that
25 precipitated them. Neuropathic pain syndromes include: diabetic neuropathy; sciatica; non-specific lower back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; post-herpetic neuralgia; trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions. These conditions are difficult to treat and although
30 several drugs are known to have limited efficacy, complete pain control is rarely achieved. The symptoms of neuropathic pain are incredibly heterogeneous and are often described as spontaneous shooting and lancinating pain, or ongoing, burning pain. In addition, there is pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias),
35 increased sensitivity to touch (hyperesthesia), painful sensation following

innocuous stimulation (dynamic, static or thermal allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).

5

The compounds of formula (I) are also useful in the treatment of inflammation, for example in the treatment of skin conditions (e.g. sunburn, burns, eczema, dermatitis, psoriasis); ophthalmic diseases such as glaucoma, retinitis, retinopathies, uveitis and of acute injury to the eye tissue (e.g. conjunctivitis); lung disorders (e.g. asthma, bronchitis, emphysema, allergic rhinitis, respiratory distress syndrome pigeon fancier's disease, farmer's lung, COPD); gastrointestinal tract disorders (e.g. aphthous ulcer, Crohn's disease, atopic gastritis, gastritis varioliforme, ulcerative colitis, coeliac disease, regional ileitis, irritable bowel syndrome, inflammatory bowel disease, gastrointestinal reflux disease); organ transplantation; other conditions with an inflammatory component such as vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anaemia, Hodgkin's disease, sclerodoma, myaesthesia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Bechet's syndrome, polymyositis, gingivitis, myocardial ischemia, pyrexia, systemic lupus erythematosus, polymyositis, tendinitis, bursitis, and Sjogren's syndrome.

10

15

20

The compounds of formula (I) are also useful in the treatment of immunological diseases such as autoimmune diseases, immunological deficiency diseases or organ transplantation. The compounds of formula (I) are also effective in increasing the latency of HIV infection.

25

The compounds of formula (I) are also useful in the treatment of diseases of abnormal platelet function (e.g. occlusive vascular diseases).

30

The compounds of formula (I) are also useful for the preparation of a drug with diuretic action.

The compounds of formula (I) are also useful in the treatment of impotence or erectile dysfunction.

35

5 The compounds of formula (I) are also useful in the treatment of bone disease characterised by abnormal bone metabolism or resorption such as osteoporosis (especially postmenopausal osteoporosis), hyper-calcemia, hyperparathyroidism, Paget's bone diseases, osteolysis, hypercalcemia of malignancy with or without bone metastases, rheumatoid arthritis, periodontitis, osteoarthritis, ostealgia, osteopenia, cancer cachexia, calculosis, lithiasis (especially urolithiasis), solid carcinoma, gout and ankylosing spondylitis, tendinitis and bursitis. In a further aspect compounds of formula (I) may be useful in inhibiting bone resorption and/or promoting bone generation.

10

The compounds of formula (I) are also useful for attenuating the hemodynamic side effects of NSAIDs and COX-2 inhibitors.

15

The compounds of formula (I) are also useful in the treatment of cardiovascular diseases such as hypertension or myocardiac ischemia; functional or organic venous insufficiency; varicose therapy; haemorrhoids; and shock states associated with a marked drop in arterial pressure (e.g. septic shock).

20

The compounds of formula (I) are also useful in the treatment of neurodegenerative diseases and neurodegeneration such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntingdon's chorea, Parkinson's disease and Creutzfeldt-Jakob disease, ALS, motor neuron disease); vascular dementia (including multi-infarct dementia); as well as dementia associated with intracranial space occupying lesions; trauma; infections and related conditions (including HIV infection); metabolism; toxins; anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment.

25

30

The compounds of formula (I) are also useful in the treatment of neuroprotection and in the treatment of neurodegeneration following stroke, cardiac arrest, pulmonary bypass, traumatic brain injury, spinal cord injury or the like.

35

The compounds of formula (I) are also useful in the treatment of tinnitus.

5 The compounds of formula (I) are also useful in preventing or reducing dependence on, or preventing or reducing tolerance or reverse tolerance to, a dependence - inducing agent. Examples of dependence inducing agents include opioids (e.g. morphine), CNS depressants (e.g. ethanol), psychostimulants (e.g. cocaine) and nicotine.

10 The compounds of formula (I) are also useful in the treatment of complications of Type 1 diabetes (e.g. diabetic microangiopathy, diabetic retinopathy, diabetic nephropathy, macular degeneration, glaucoma), nephrotic syndrome, aplastic anaemia, uveitis, Kawasaki disease and sarcoidosis.

15 The compounds of formula (I) are also useful in the treatment of kidney dysfunction (nephritis, particularly mesangial proliferative glomerulonephritis, nephritic syndrome), liver dysfunction (hepatitis, cirrhosis), gastrointestinal dysfunction (diarrhoea) and colon cancer.

20 It is to be understood that reference to treatment includes both treatment of established symptoms and prophylactic treatment, unless explicitly stated otherwise.

According to a further aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in human or veterinary medicine.

25 According to another aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by the action of PGE₂ at EP4 receptors.

30 According to a further aspect of the invention, we provide a method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE₂ at EP4 receptors which comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

According to a further aspect of the invention we provide a method of treating a human or animal subject suffering from a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder, which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

According to another aspect of the invention, we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a therapeutic agent for the treatment of a condition which is mediated by the action of PGE₂ at EP4 receptors.

According to another aspect of the invention we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a therapeutic agent for the treatment or prevention of a condition such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

The compounds of formula (I) and their pharmaceutically acceptable derivatives are conveniently administered in the form of pharmaceutical compositions. Such compositions may conveniently be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or excipients.

Thus, in another aspect of the invention, we provide a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof adapted for use in human or veterinary medicine.

The compounds of formula (I) and their pharmaceutically acceptable derivatives may be formulated for administration in any suitable manner. They may, for example, be formulated for topical administration or administration by inhalation or, more preferably, for oral, transdermal or parenteral administration. The pharmaceutical composition may be in a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable derivatives.

For oral administration, the pharmaceutical composition may take the form of, for example, tablets (including sub-lingual tablets), capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.

5

For transdermal administration, the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.

10

For parenteral administration, the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravascularly or subcutaneously). The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. For administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably with an added preservative.

15

Alternatively for parenteral administration the active ingredient may be in powder form for reconstitution with a suitable vehicle.

20

The compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

25

The EP4 receptor compounds for use in the instant invention may be used in combination with other therapeutic agents, for example COX-2 inhibitors, such as celecoxib, rofecoxib, valdecoxib or parecoxib; 5-lipoxygenase inhibitors; NSAID's, such as diclofenac, indomethacin, nabumetone or ibuprofen; leukotriene receptor antagonists; DMARD's such as methotrexate; adenosine A1 receptor agonists; sodium channel blockers, such as lamotrigine; NMDA receptor modulators, such as glycine receptor antagonists; gabapentin and related compounds; tricyclic antidepressants such as amitriptyline; neurone

30

35

stabilising antiepileptic drugs; mono-aminergic uptake inhibitors such as venlafaxine; opioid analgesics; local anaesthetics; 5HT₁ agonists, such as triptans, for example sumatriptan, naratriptan, zolmitriptan, eletriptan, frovatriptan, almotriptan or rizatriptan; EP1 receptor ligands; EP2 receptor
5 ligands; EP3 receptor ligands; EP1 antagonists; EP2 antagonists and EP3 antagonists. When the compounds are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.

10 The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent or agents.

The combinations referred to above may conveniently be presented for use in
15 the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical
20 formulations.

When a compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the
25 same disease state the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.


A proposed daily dosage of compounds of formula (I) or their pharmaceutically acceptable salts for the treatment of man is from 0.01 to 10 mg/kg body weight
30 per day and more particularly 0.1 to 3 mg/kg body weight per day, calculated as the free base, which may be administered as a single or divided dose, for example one to four times per day. The dose range for adult human beings is generally from 8 to 1000 mg/day, such as from 20 to 800 mg/day, preferably 35 to 200 mg/day, calculated as the free base.

The precise amount of the compounds of formula (I) administered to a host, particularly a human patient, will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors including the age and sex of the patient, the precise condition being treated and its severity, and the route of administration.


Compounds of formula (I) and pharmaceutically acceptable derivatives thereof may be prepared by any method known in the art for the preparation of compounds of analogous structure.

Compounds of formula (I) and pharmaceutically acceptable derivatives thereof may be prepared by a process which comprises:

(A), coupling a sulfonamide of formula (II)




or a protected derivative thereof with an acid chloride of formula (III)




or a protected derivative thereof; or

(B), coupling a sulfonamide of formula (II)

17



or a protected derivative thereof with an acid of formula (IV)



or a protected derivative thereof; or

5

(C), interconversion of a compound of formula (I) into another compound of formula (I); or

(D), deprotecting a protected derivative of compound of formula (I); and

10

optionally converting compounds of formula (I) prepared by any one of the processes (A) to (D) into pharmaceutically acceptable derivatives thereof.

15

Suitable methods for the preparation of compounds of formula (I) and pharmaceutically acceptable derivatives thereof are described below, and form a further aspect of the invention. In the Schemes that follow, R¹ to R¹² are as defined in formula (I) above unless otherwise stated; DMF is dimethylformamide; DCM is dichloromethane; TFA is trifluoroacetic acid; DMAP is dimethylaminopyridine; Ac is acetyl; Hal is halogen.


20

Referring to Scheme 1 that follows, compounds of formula (I), wherein a is 1, R³ is O and R⁴ is H, may be prepared by coupling a compound of formula (II) with an acid chloride of formula (III) in the presence of a non-nucleophilic base, such as potassium carbonate or DMAP, in a suitable aprotic solvent such as acetone or toluene. In one embodiment of Scheme 1, potassium carbonate is added to a

25

solution comprising a compound of formula (II) and an acid chloride of formula (III) in acetone. The reaction mixture is then heated at about 80°C under nitrogen for about 18h. The reaction is then allowed to cool to ambient temperature and filtered to remove remaining solid. The filtrate is acidified using 2N hydrochloric acid and then diluted with water. The precipitate is then filtered off and triturated with diethylether to give a compound of formula (I), wherein a is 1, R³ is O and R⁴ is H, as a solid. In another embodiment of Scheme 1, DMAP is added to a solution comprising a compound of formula (II) and an acid chloride of formula (III) in toluene. The reaction mixture is then heated at about 120°C under nitrogen for about 18h. The reaction is then allowed to cool to ambient temperature and concentrated *in vacuo*. The residue is purified by chromatography eluting with ethyl acetate. The filtrate is then concentrated *in vacuo* and triturated with diethylether to give a compound of formula (I), wherein a is 1, R³ is O and R⁴ is H, as a solid.


Scheme 1



Referring to Scheme 2 that follows, compounds of formula (I), wherein a is 1, R³ is O and R⁴ is H, may also be prepared by coupling a compound of formula (II)

with an acid of formula (IV) in the presence of an activating agent, such as a carbodiimide, and a hindered organic amine base, such as DMAP, in a suitable aprotic solvent, such as DMF. Such couplings are described in many organic texts such as 'Principles of Peptide Synthesis' by Miklos Bodanszky (Springer Verlag, 1984) chapter 2, incorporated herein by reference. In one embodiment of
5 Scheme 2, polymer supported carbodiimide (available from Argonaut Technologies, Inc.) is added to a solution comprising a compound of formula (II), DMAP and an acid of formula (IV) in DMF/DCM. The reaction mixture is then shaken at ambient temperature for about 18h. The reaction mixture is then
10 filtered and the resin is washed with DCM. The combined filtrate and washings are subject to an amino propyl SPE cartridge. Impurities are removed by elution with methanol and the desired product is removed by elution with methanol/acetic acid. The product filtrate is concentrated *in vacuo* and then triturated with methanol to give a compound of formula (I), wherein a is 1, R³ is
15 O and R⁴ is H, as a solid.

Scheme 2



Compounds of formula (I) wherein R^3 is H may be synthesised in a manner analogous to Scheme 1 or 2. In this case, compounds of formula (II) are first converted to compounds corresponding to those of formula (II) wherein one of the C=O groups is converted to CH_2 via reduction with a suitable reducing agent. A suitable reducing agent is sodium borohydride in methanol followed by TFA and triethylsilane.


Acid chlorides of formula (III) and acids of formula (IV) are either known compounds or may be prepared by literature methods such as those described in 'Advanced Organic Chemistry' by Jerry March, fourth edition (John Wiley & Sons, 1992) page 1269 column 2, and page 1280 column 2, incorporated herein by reference.

It will be appreciated by those persons skilled in the art that compounds of formula (I) may be prepared by interconversion, utilising other compounds of formula (I) as precursors. In particular, alkylations are well known to those skilled in the art and are described in many standard organic chemistry texts such as 'Advanced Organic Chemistry'. For example, compounds of formula (I) wherein R^4 is C_{1-6} alkyl can be prepared by alkylating compounds of formula (I) wherein R^4 is H. Suitable alkylating agents include C_{1-6} alkyl iodides.

As will be appreciated by those skilled in the art, it may be necessary or desirable at any stage in the synthesis of compounds of formula (I) to protect one or more sensitive groups in the molecule so as to prevent undesirable side reactions. The protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See, for example, those described in 'Protective Groups in Organic Synthesis' by Theodora W Green and Peter G M Wuts, second edition (John Wiley and Sons, 1991), incorporated herein by reference, which also describes methods for the removal of such groups.


Compounds of formula (II) may, for example, be prepared according to Scheme 3 that follows.

Scheme 3




(i) Na, EtOH; (ii) K_2CO_3 , R^2Hal , acetone; (iii) NaOH, aq. EtOH;

(iv) , AcOH



Compounds of formula (V) may, for example, be prepared according to Scheme 4 that follows.

Scheme 4



5

Phthalates of formula (IX) are either known compounds or may be prepared by conventional chemistry from commercially available starting materials.

10 4-Nitrobenzyl chlorides of formula (XII) are either known compounds or may be prepared by conventional chemistry from commercially available starting materials.

15 Compounds of formula (I) wherein $a = 0$, may be synthesised in an analogous manner. In this case the compounds analogous to those of formula (V) but not possessing the CHR^{11} moiety are commercially available thus rendering Scheme 4 unnecessary.

Certain intermediates described above are novel compounds, and it is to be understood that all novel intermediates herein form further aspects of the present invention.

- 5 Solvates (e.g. hydrates) or salts of a compound of the invention may be formed during the work-up procedure of any one of the aforementioned process steps.

10 The Intermediates and Examples that follow illustrate the invention but do not limit the invention in any way. All temperatures are in °C. ¹H nmr spectra were obtained at 400MHz on a Bruker DPX400. Mass directed autopurification was performed using a system comprising a HP1100 HPLC, a Gilson Aspec Autosampler, a HP1050 Make up Pump, a Micromass Platform Mass Spectrometer, a LC Packings Prep Accurate Combi-Chem Flow Processor (ACM-01-10), a Supelco 5µm ABZ+ 5cm x 10mm ID Column and a Gilson
15 Fraction Collector. The samples were dissolved in 50:50 acetonitrile:dimethylsulfoxide. A suitable gradient elution determined on the basis of the retention time of the compound in LC/MS was employed, for example 20-50% acetonitrile or 30-60% acetonitrile in water. The determination of such gradient elutions will be appreciated by those skilled in the art.

20

Intermediate 1

Ethyl 1,4-dihydroxy-2,3-naphthalenedicarboxylate

25 Sodium (60g, 2.6mol) was dissolved in ethanol (1.2l) and the mixture was cooled to 40°C. Diethylphthalate (960ml, 4.83mol) was added and the mixture heated under nitrogen until the temperature reached 115°C. Diethyl succinate (211.3g, 1.21mol) was added dropwise over 45 min. The reaction was heated at 115°C for a further 45 min, cooled to room temperature and poured onto water (1.2l). Ethyl acetate (1l) was added and stirred, the layers were separated and the
30 organics were extracted with sodium hydroxide solution (2N, 1l). The combined aqueous was acidified to pH 3 and the mixture extracted with ethyl acetate (2 x 1l). The combined organics were washed with a saturated solution of sodium hydrogen carbonate (2 x 1.5l), then brine, dried (MgSO₄), filtered and the solvent evaporated under vacuum. The residue was purified using a 2.5kg Biotage column eluting with 5% ethyl acetate/hexane to give the title compound as a

white solid, (60g, 16%). δ H CDCl₃ 10.44,(2H, s), 8.34,(2H, m), 7.68,(2H, m), 4.37,(4H, q), 1.37,(6H, t).

Intermediate 2

5 Ethyl 1,4-diethoxy-2,3-naphthalenedicarboxylate

Ethyl 1,4-dihydroxy-2,3-naphthalenedicarboxylate (30g, 98.6 mmol) and potassium carbonate (150g, 1.09mmol) were stirred in acetone (600ml) under nitrogen. Iodoethane (150g, 0.96mol) was added and the mixture was stirred at reflux overnight. The reaction was cooled, diluted with ethyl acetate and filtered. The filtrate was evaporated to leave a brown oil, which was dissolved in toluene and washed with potassium hydroxide solution (5%, 150ml) and brine. Drying over magnesium sulphate and evaporation of the solvent gave a yellow solid. Purification using an 800g Biotage column gave the title compound as a white solid (32g, 90%). δ H CDCl₃ 8.16,(2H, m), 7.60,(2H, m), 4.40,(4H, q), 4.18,(4H, q), 1.50,(6H, t), 1.40,(6H, t).

Intermediate 3

1,4-Diethoxy-2,3-naphthalenedicarboxylic acid

Ethyl 1,4-diethoxy-2,3-naphthalenedicarboxylate (32g, 89mmol) was added to a solution of sodium hydroxide (20g) in ethanol (200ml) and water (40ml) and stirred for 1.5h at 60°C. The reaction was cooled and the thick white suspension was filtered. The solid was dissolved in a mixture of ethyl acetate (200ml) and water (800ml). The layers were separated and the aqueous was acidified with hydrochloric acid (2M, 120ml). The aqueous was extracted with ethyl acetate (2x) and the combined organics were dried (MgSO₄). Evaporation of the solvent under vacuum gave the title compound as a white solid (25g, 92%). δ H [²H₆] – DMSO 13.26,(2H, s), 8.15,(2H, m), 7.72,(2H, m), 4.13,(4H, q), 1.42,(6H, t).

Intermediate 4

30 4-nitrobenzyl imidothiocarbamate hydrochloride

A mixture of 4-nitrobenzylchloride (Aldrich, 85.8g, 0.5mol) and thiourea (Aldrich, 38.1g, 0.5mol) in ethanol (250ml) was heated to reflux, under nitrogen, for 2.5h. The reaction mixture was allowed to cool to ambient temperature and the precipitate was filtered off. The solid was washed with ethanol and diethylether and then dried *in vacuo* to give the title compound as a white solid (112.4g,

90.8%). δH [2H_6] – DMSO 4.72 (2H, s); 7.74 (2H, d, 9.4Hz); 8.25 (2H, d, 9.4Hz); 9.41 (3H, bds).

Intermediate 5

5 4-Nitro-benzylsulfonamide

Through a solution of Intermediate 4 (112.4g, 0.45mol) in water (2400ml) was bubbled chlorine gas for 6h at $<12^\circ C$. The reaction mixture was extracted with ethyl acetate (x2) and the combined organic phases washed with water and brine. The precipitate, which formed on standing, was filtered off and discarded.
10 The filtrate was concentrated *in vacuo* to give a oily yellow solid (70g). This solid was added portionwise, with cooling, to .880 ammonia (450ml). The mixture was stirred at ambient temperature for 1.5h and then diluted with water (750ml). The resultant precipitate was filtered off, washed with water and dried *in vacuo* to give a pale yellow solid (25.5g). This was heated in acetonitrile and filtered whilst hot.
15 The filtrate was concentrated *in vacuo* and dried to give the title compound as a white solid (17.53g, 18%). δH [2H_6] – DMSO 4.48 (2H, s); 6.99 (2H, s); 7.66 (2H, d, 9.5Hz); 8.23 (2H, d, 9.5Hz).

Intermediate 6

20 4-Amino-benzylsulfonamide

To 10% palladium on charcoal catalyst (3g, 50% wet with water) under a nitrogen atmosphere was added a solution of 4-nitro-benzylsulfonamide (17.53g, 81.1mmol) in dimethylformamide (175ml). The atmosphere of nitrogen was replaced with hydrogen and the mixture stirred vigorously for 5h. The
25 atmosphere was replaced with nitrogen and the mixture filtered through celite. The solvent was removed *in vacuo* and the residue triturated with diethylether to give a dark brown solid (14.7g). The solid was heated in acetonitrile (440ml) and filtered whilst hot (to remove excess catalyst). The filtrate was allowed to cool and the precipitate filtered off and dried *in vacuo* to give the title compound as a
30 beige solid (12.32g, 82%). δH [2H_6] – DMSO 4.05 (2H, s); 5.11 (2H, s); 6.53 (2H, d, 8.2Hz); 6.63 (2H, s); 7.01(2H,d, 8.2Hz).

Intermediate 7

35 1-[4-(4,9-diethoxy-1,3-dioxo-1,3-dihydro-2H-benzof[fi]isoindol-2-yl)phenyl]methanesulfonamide

To a solution of 1,4-diethoxy-2,3-naphthalenedicarboxylic acid (0.75g, 2.5mmol, 1.1eqs) in glacial acetic acid (5ml) was added 4-amino-benzylsulfonamide (0.43g, 2.3mmol). The reaction mixture was heated at 120°C for 18h. The reaction mixture was allowed to cool to ambient temperature and then poured into water (5ml). The precipitate was filtered off, triturated with ethyl acetate/40:60 petroleum ether and then dried *in vacuo* to give the title compound as a beige solid (790mg, 69%). δ H [2 H₆] – DMSO 1.48 (6H, t); 4.40 (2H, s); 4.52 (4H, q); 7.00 (2H, s); 7.51 (2H, d, 8.5Hz); 7.56 (2H, d, 8.5Hz); 7.89 (2H, m); 8.43 (2H, m)

Intermediate 8

1-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzoflisoindol-2-yl)phenyl]methanesulfonamide

Sodium borohydride (0.5M solution in 2-methoxy ethyl ether, 56ml, 23mmol, 3.5eqs) was added portionwise over 2h to a suspension of Intermediate 7 (3g, 6.6mmol) in anhydrous methanol (60ml) keeping the temperature below 0°C. The reaction mixture was stirred under nitrogen at 0°C for a further 0.5h. The reaction was quenched with saturated ammonium chloride solution (50ml) and extracted with ethylacetate (x3). The combined organic extracts were dried (Na₂SO₄) and then concentrated *in vacuo* to give a pale yellow solid/oil. The solid/oil was added portionwise to trifluoroacetic acid (15ml) at 0°C. Triethylsilane (1.48ml, 9.3mmol, 1.4eqs) was added and stirring continued at 0°C for 10mins. The temperature was allowed to reach ambient and stirring continued for a further 10mins. The reaction mixture was concentrated *in vacuo* and the residue triturated with diethylether to give the title compound as a pink solid (2.3g, 79%). δ H [2 H₆] – DMSO 1.44 (3H, t); 1.50 (3H, t); 4.27 (2H, m); 4.30 (2H, q); 4.38 (2H, q); 5.18 (2H, s); 6.85 (2H, s); 7.43 (2H, d, 9Hz); 7.57 – 7.75 (2H, m); 8.01 (2H, d, 9Hz); 8.20 (1H, d, 9.4Hz); 8.32 (1H, d, 9.4Hz).

Example 1


1-[4-(4,9-diethoxy-1,3-dioxo-1,3-dihydro-2H-benzoflisoindol-2-yl)phenyl]-N-(phenylacetyl)methanesulfonamide

To a solution of Intermediate 7 (40mg, 0.088mmol) and phenylacetyl chloride (77mg, 0.5mmol, 5.7eqs) in acetone (3.5ml) was added potassium carbonate (100mg, 0.72mmol, 8.2eqs). The reaction mixture was heated at 80°C under

nitrogen for 18h. The reaction was allowed to cool to ambient temperature and then filtered to remove remaining solid. The filtrate was acidified using 2N hydrochloric acid and then diluted with water. The precipitate was filtered off and then triturated with diethylether to give the title compound as a beige solid (22mgs, 43%). MH⁺ 573.

The examples of Table 1 were prepared in the manner described for Example 1.

Table 1




Ex	a	b	R ¹	R ³	R ⁵	R ⁶	R ¹²	MH ⁺
2	1	1	H	O	H	H	4-methoxyphenyl	603
3	1	0	H	O	-	-	4-cyanophenyl	584
4	1	0	H	O	-	-	phenyl	559
5	1	0	H	O	-	-	3-fluorophenyl	577
6	1	0	H	O	-	-	4-nitrophenyl	604
7	1	0	H	O	-	-	4-fluorophenyl	577
8	1	0	H	O	-	-	methyl	497
9	1	0	H	O	-	-	n-butyl	539
10	1	0	H	O	-	-	t-butyl	539
11	1	0	H	O	-	-	cyclohexyl	565
12	1	1	H	O	H	H	OC(O)CH ₃	555
13	1	0	H	O	-	-	naph-2-yl	609
14	1	0	H	O	-	-	5-methyl-1,2-oxazol-5-yl	564
15	1	2	H	O	H	H	phenyl	587
16	1	2	H	O	H	H	cyclohexyl	593
17	1	0	H	O	-	-	furan-2-yl	549


Example 181-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzof[*f*]isoindol-2-yl)phenyl]-N-(phenylacetyl)methanesulfonamide

To a solution of Intermediate 8 (176mg, 0.4mmol) and phenylacetyl chloride (210mg, 1.36mmol, 3.4eqs) in toluene (16ml) was added 4-dimethylaminopyridine (100mg, 0.8mmol, 2eqs). The reaction mixture was heated at 120°C under nitrogen for 18h. The reaction was allowed to cool to ambient temperature and then concentrated *in vacuo*. The residue was purified on a silica gel SPE cartridge eluting with ethylacetate. The filtrate was concentrated *in vacuo* and then triturated with diethylether to give the title compound as a cream solid (130mg, 57.5%). MH^+ 559.

The examples of Table 2 were prepared in the manner described for Example 18.


Table 2

Ex	a	b	R ¹	R ³	R ⁵	R ⁶	R ¹²	MH ⁺
19	1	1	H	H	H	H	3,4-dichlorophenyl	627
20	1	1	H	H	H	H	4-methylphenyl	573
21	1	1	H	H	H	H	2-methylphenyl	573
22	1	1	H	H	Me	Me	phenyl	587
23	1	1	H	H	H	H	4-i-butylphenyl	615
24	1	1	H	H	H	H	4-methoxyphenyl	617
25	1	1	H	H	H	H	3-fluorophenyl	577
26	1	1	H	H	H	H	3-methylphenyl	573
27	1	1	H	H	H	H	4-i-propylphenyl	601
28	1	1	H	H	H	H	4-ethylphenyl	587

29	1	1	H	H	H	H	2-chlorophenyl	593
30	1	1	H	H	H	H	4-phenylphenyl	635
31	1	1	H	H	H	H	2-methoxyphenyl	589
32	1	1	H	H	H	H	2-fluorophenyl	577
33	1	1	H	H	H	H	4-trifluoromethylphenyl	627
34	1	1	H	H	H	H	2,3-dimethoxyphenyl	619
35	1	1	H	H	H	H	4-hydroxyphenyl	575
36	1	1	H	H	H	H	2,5-dimethoxyphenyl	619
37	1	1	H	H	H	H	4-dimethylaminophenyl	602
38	1	1	H	H	H	H	3,4-dimethoxyphenyl	619
39	1	1	H	H	H	H	2,5-dimethylphenyl	587
40	1	1	H	H	Me	H	4-i-butylphenyl	629
41	1	1	H	H	H	H	2-benzyloxyphenyl	665
42	1	1	H	H	H	H	3-benzyloxyphenyl	665
43	1	1	H	H	H	H	3-methoxyphenyl	589
44	1	1	H	H	H	H	2-(CH ₂ CO ₂ H)phenyl	617
45	1	1	H	H	H	H	4-(CO ₂ Me)phenyl	617
46	1	1	H	H	H	H	4-(SO ₂ NMe ₂)phenyl	666
47	1	1	H	H	H	H	2-(CH ₂ CO ₂ Me)phenyl	631
48	1	1	H	H	H	H	naphth-2-yl	609
49	1	0	H	H	-	-		571
50	1	1	H	H	cyclopropyl		phenyl	585
51	1	1	H	H	H	H	thiophen-3-yl	565
52	1	1	H	H	H	H	pyridin-3-yl	560
53	1	1	H	H	H	H	thiophen-2-yl	565
54	1	1	H	H	H	H	pyridin-2-yl	560
55	1	1	H	H	H	H	pyridin-4-yl	560
56	1	1	H	H	H	H	2-methyl-1,3-thiazol-4-yl	580
57	1	1	H	H	H	H	4-methyl-1,2,5-oxadiazol-3-yl	565
58	1	1	H	H	H	H	5-methyl-1,2-oxazol-3-yl	564
59	1	1	H	H	H	H	3-methyl-1,2-oxazol-5-yl	564
60	1	1	H	H	H	H	4-methyl-1,3-thiazol-5-yl	580

The examples of Table 3 were prepared in the manner described for Example 18 except Intermediate 8 was replaced with intermediate 7.

5 Table 3




Ex	a	b	R ¹	R ³	R ⁵	R ⁶	R ¹²	MH ⁺
61	1	1	H	O	H	H	2-methylphenyl	587
62	1	1	H	O	H	H	4-fluorophenyl	591
63	1	1	H	O	H	H	3-methoxyphenyl	603
64	1	1	H	O	Et	H	phenyl	601
65	1	1	H	O	H	H	3-fluorophenyl	591
66	1	1	H	O	H	H	3,4-dimethoxyphenyl	633
67	1	1	H	O	H	H	4-methylphenyl	587
68	1	1	H	O	Me	H	phenyl	587
69	1	1	H	O	H	H	2,5-difluorophenyl	609
70	1	1	H	O	H	H	4-chlorophenyl	607
71	1	1	H	O	H	H	2-methoxyphenyl	603
72	1	1	H	O	H	H	2,6-dimethylphenyl	601
73	1	1	H	O	Me	Me	3-methylphenyl	615
74	1	1	H	O	H	H	3-fluoro-4-methylphenyl	605
75	1	1	H	O	Cl	H	phenyl	607
76	1	1	H	O	H	H	naphth-1-yl	623
77	1	1	H	O	H	H	naphth-2-yl	623
78	0	0	H	O	-	-	methyl	555

Example 79








1-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzof[*f*]isoindol-2-yl)phenyl]-N-[(4-methyl-1,3-thiazol-5-yl)acetyl]methanesulfonamide

To a solution of Intermediate 8 (44mg, 0.1mmol), 1-[4-methyl-1,3-thiazol-5-yl]acetic acid (32mg, 0.2mmol, 2eqs) and 4-dimethylaminopyridine (74mg, 0.6mmol, 6eqs) in dimethylformamide (2ml) and dichloromethane (2ml) was added polymer supported carbodiimide (Argonaut Technologies, Inc., 480mg, 0.45mmol, 4.5eqs). The reaction mixture was shaken at ambient temperature for 18h. The reaction was filtered and the resin washed with dichloromethane. The combined filtrate and washings were subject to an amino propyl SPE cartridge. Impurities were removed by elution with methanol and the required product was removed by elution with methanol/acetic acid. The product filtrate was concentrated *in vacuo* and then triturated with methanol to give the title compound as a beige solid. MH⁺ 580.


The examples of Table 4 were prepared in the manner described for Example 79.

Table 4

Ex	a	b	R ¹	R ³	R ⁵	R ⁶	R ¹²	MH ⁺
80	1	1	H	H	H	H	4-trifluoromethoxyphenyl	643
81	1	1	H	H	H	H	3-trifluoromethoxyphenyl	643
82	1	1	H	H	H	H	3,4-diethoxyphenyl	647
83	1	1	H	H	H	H	3,5-dimethoxyphenyl	619
84	1	1	H	H	H	H		603

85	1	1	H	H	H	H		631
86	1	1	H	H	Me	H	6-methoxy-naphth-2-yl	653
87	1	1	H	H	H	H		598
88	1	1	H	H	H	H		599
89	1	1	H	H	H	H		612
90	1	1	H	H	H	H		599
91	1	0	H	H	-	-		603
92	1	0	H	H	-	-		626

The example of Table 5 was prepared in the manner described for Example 79 except Intermediate 8 was replaced with Intermediate 7.



Ex	a	b	R ¹	R ³	R ⁵	R ⁶	R ¹²	MH ⁺
93	1	1	H	O	H	H		617

Example 94

1-[4-(4,9-diethoxy-1,3-dioxo-1,3-dihydro-2H-benzof[f]isoindol-2-yl)phenyl]-N-[(4-methoxyphenyl)acetyl]-N-methyl-methanesulfonamide

To a solution of the product of Example 2 (40mg, 0.066mmol) and methyl iodide (0.032ml, 0.51mmol, 7.7eqs) in acetonitrile (5ml) was added sodium carbonate (14mg, 0.133mmol, 2eqs). The reaction mixture was stirred at ambient temperature under nitrogen for 18h. The reaction was concentrated *in vacuo* and then partitioned between ethylacetate (20ml) and 2N hydrochloric acid (20ml). The organic phase was washed with brine, dried (MgSO₄) and then concentrated *in vacuo*. The residue was preabsorbed onto silica and purified on a silica gel SPE cartridge eluting with an ethylacetate/petroleum ether gradient. The solvent was removed *in vacuo* to give the title compound as a yellow solid (15mg, 36%). MH⁺ 617.

Biological Data

The ability of the compounds to bind to EP₄ receptors may be demonstrated in the Human EP₄ Scintillation Proximity Assay.

Quantification of radioligand binding by scintillation proximity assay (SPA) is a long-established principle. Briefly, the affinity of compounds for a receptor is assessed by the specific competition between known quantities of radiolabelled ligand and compound for that receptor. Increasing concentrations of compound reduce the amount of radiolabel that binds to the receptor. This gives rise to a

diminishing scintillation signal from SPA beads coated with membranes that bear the receptor. The signal may be detected with a suitable scintillation counter and the data generated may be analysed with suitable curve-fitting software.

- 5 The human EP₄ SPA assay (hereafter referred to as 'the assay') utilises membranes prepared from Chinese Hamster Ovary (CHO cells) infected with Semliki Forest Virus (SFV). Genetically engineered SFV-1 viral particles containing the genetic sequence of the human EP₄ receptor were used to infect
- 10 CHO cells resulting in expression of the receptor protein in cellular membranes. Cells washed free of media are homogenised in a pH-buffered medium containing peptidase inhibitors. A suitable buffer is of the following composition: 50mM HEPES, 1mM EDTA, 25µg/ml bacitracin, 100µM leupeptin, 1mM PMSF, 2µM Pepstatin A, pH adjusted to 7.4 with KOH. Following removal of cell debris
- 15 by a low-speed centrifugation, a pellet of membranes is prepared by a high-speed (48000g) centrifugation of the resulting supernatant. Membrane suspensions such as that described may be stored at -80°C until used.

- For assay, membranes expressing human EP₄ receptors are diluted in a pH-buffered medium and mixed with SPA beads coated with a suitable substance to
- 20 facilitate the adhesion of membranes to the beads. The concentrations of membrane protein and SPA beads chosen should result in SPA binding signal of at least 300 corrected counts per minute (CCPM) when tritiated radioligand at a concentration close to its K_d (affinity value) is combined with the mixture. Non-specific binding (nsb) may be determined by competition between the
- 25 radiolabelled ligand and a saturating concentration of unlabelled ligand. In order to quantify the affinity of EP₄ receptor ligands, compounds are diluted in a stepwise manner across the wells of a 96-well plate. Radioligand, compound, and unlabelled ligand are then added to a 96-well plate suitable for the measurement of SPA binding signals prior to the addition of bead / membrane
- 30 mixture to initiate the binding reaction. Equilibrium may be achieved by incubation at room temperature for 120 minutes prior to scintillation counting. The data so generated may be analysed by means of a computerised curve-fitting routine in order to quantify the concentration of compound that displaces 50% of the specific radioligand binding (IC₅₀). The affinity (pK_i) of the compound
- 35 may be calculated from the IC₅₀ by application of the Cheng-Prusoff correction.

Suitable reagents and protocols are: reaction buffer containing 50mM HEPES, 10mM MgCl₂, pH adjusted to 7.4 with KOH; SPA beads coated with wheatgerm agglutinin; 1.25nM [³H]-prostaglandin E₂ as radioligand; 10μM prostaglandin E₂ as unlabelled ligand; a three-fold dilution series of compound starting at 10μM and ending at 0.3nM is adequate.

The ability of the compounds to antagonise EP4 receptors may be demonstrated in the [¹²⁵I]cAMP Scintillation Proximity Assay (hereafter referred to as 'the cAMP assay'). The cAMP assay utilises HEK-293 cells expressing the recombinant human EP4 receptor, obtained from Receptor Biology, Inc. Beltsville, MD, USA. The cells are cultured in Dulbecco's Modified Eagle Medium – HAM F12 mix (DMEM-F12), containing 10% heat inactivated-foetal bovine serum (FBS) and 2mM L-glutamine. The cells are either passaged into fresh medium or used in an assay once 90% confluency as determined visually had been achieved.

The cells are harvested by treatment with Versene, re-suspended in fresh culture medium and plated out to yield approximately 10,000 cells per well of a 96-well plate for overnight culture in culture medium additionally supplemented with 3μM indomethacin. For assay, the culture medium is replaced with assay medium (DMEM-F12 containing 300μM isobutylmethylxanthine (IBMX) and 3μM indomethacin) and incubated for 30 minutes. Following this, antagonist is then added at various concentrations such that an entire agonist concentration-effect curve can be obtained in the presence of a single concentration of the antagonist. The antagonist is allowed to equilibrate with the cells for 30 minutes. Subsequently the cells are challenged with an agonist for 15 minutes. The reaction is stopped by the aspiration of the assay medium and the addition of ice-cold ethanol. All incubations are carried out at 37°C in a 5% carbon dioxide atmosphere. Care must be taken to ensure the constancy of IBMX, indomethacin and vehicle (DMSO) concentrations throughout. The amount of cAMP in each well is then determined by [¹²⁵I]cAMP scintillation proximity assay using a proprietary kit, obtained from Amersham, Buckinghamshire, UK, and according to the manufacturer's instructions.

Data from cAMP assays are expressed as pmol cAMP per well. A four-parameter logistic equation of the form:

$$E = (Em \cdot [A]^{nH}) / ((EC_{50}^{nH}) + ([A]^{nH}))$$

is then fitted to E/[A] curve data in order to estimate maximum effect (Em), curve mid-point (EC50), and Hill slope (nH); other terms in the equation are effect (E) and concentration ([A]). Individual estimates of curve parameters are obtained from each curve. An empirical estimate of antagonist affinity (pA₂) could then be obtained using the following formula:

$$pA_2 = \log ((EC_{50}^B / EC_{50}^A) - 1) - \log[B]$$

where EC₅₀^A is the midpoint of a control agonist concentration-effect curve in the absence of antagonist; EC₅₀^B is the midpoint of an agonist concentration effect curve produced in the presence of a fixed concentration of antagonist; and [B] is the concentration of antagonist used. Estimates from individual experiments are then averaged to provide mean data. Quoted values are therefore the mean ± standard deviation (s.d.) of n separate experiments, each derived from a separate cAMP assay.


For the rigorous estimation of antagonist affinity values (pK_b) the method of Arunlakshana and Schild is employed. Briefly, the midpoint of agonist concentration/effect curves in the presence and absence of antagonist are used to calculate concentration ratios (CR). Linear regression is performed on a plot of (CR-1) against concentration of antagonist (-log[B]) in order to estimate the point of intersection with the concentration (-log[B]) axis and the slope of the line. If the slope of the regression does not differ significantly from unity then it may be constrained to 1.0. Under this latter circumstance, the point of intersection on the concentration axis represents the affinity (pK_b) of the antagonist.

The following examples have a pK_i of 7.0 or greater at EP4 receptors as determined using the above-mentioned procedure:

1, 2, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 36, 38, 39, 40, 42, 43, 47, 48, 50, 51, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 80, 81, 82, 83, 84, 85, 86, 87, 88, 92 and 93.

Claims

1. Compounds of formula (I)



5

and pharmaceutically acceptable derivatives thereof in which:

$a = 0$ or 1 ;

$b = 0$ to 3 ;

10 R^1 is H, halogen, C_{1-6} alkyl, $S-C_{1-6}$ alkyl, C_{1-6} alkoxy, OCF_3 , OCH_2CF_3 , O-cyclopropyl, OCH_2 -cyclopropyl, NH_2 , NHC_{1-6} alkyl, $N(C_{1-6}alkyl)_2$, NO_2 , OH, $CH_2OC_{1-6}alkyl$ or CH_2OH ;

each R^2 is independently selected from $C_{1-4}alkyl$;

R^3 is H or O;

R^4 is H or $C_{1-6}alkyl$;

15

R^5 and R^6 are each independently selected from H, halogen, $C_{1-3}alkyl$, or are taken together to form a cyclopropyl ring;

R^7 to R^{10} are each independently selected from H, $C_{1-6}alkyl$, $C_{1-6}alkoxy$, $C_{1-6}alkoxy$ substituted by one or more fluorine atoms, O-cyclopropyl, OCH_2 -cyclopropyl, $S-C_{1-6}alkyl$, NH_2 , $NHC_{1-6}alkyl$, $N(C_{1-6}alkyl)_2$, halogen, NO_2 , OH, $CH_2OC_{1-6}alkyl$, CH_2OH ;

20

R^{11} is selected from H, OH, halogen, dihalogen, NH_2 , $NHC_{1-6}alkyl$, $N(C_{1-6}alkyl)_2$, $C_{1-6}alkyl$, $C_{1-6}dialkyl$, $C_{1-6}alkoxy$, $NHCO(C_{1-6}alkyl)$, or $=O$;

R^{12} is selected from H, $C_{1-6}alkyl$, phenyl, phenyl substituted by one or more R^{13} , phenyl fused to a heterocycle, naphthyl, naphthyl substituted by one or more R^{13} , $C_{4-7}cycloalkyl$, $C_{4-7}cycloalkyl$ fused to a benzene ring, $OCOC_{1-6}alkyl$, heteroaryl or heteroaryl substituted by one or R^{13} ;

25

R^{13} is halogen, $C_{1-6}alkyl$, $C_{1-6}alkyl$ substituted by one or more fluorine atoms, $C_{1-6}alkoxy$, $C_{1-6}alkoxy$ substituted by one or more fluorine atoms,


phenyl, CN, CO₂H, CO₂C₁₋₆alkyl, OH, NH₂, NHC₁₋₆alkyl, N(C₁₋₆alkyl)₂, S(O)_nC₁₋₆alkyl where n is 0, 1 or 2, SO₂N(C₁₋₆alkyl)₂, CONH₂, CONHC₁₋₆alkyl, CON(C₁₋₆alkyl)₂, COC₁₋₆alkyl, benzyloxy, CH₂CO₂H, CH₂CO₂C₁₋₆alkyl, NO₂ or NHCO(C₁₋₆alkyl);

---- is a single bond or, when R³ is O, a double bond.


- 5
2. Compounds as claimed in claim 1 wherein a = 1.
3. Compounds as claimed in claim 1 or 2 wherein b = 1.
- 10 4. Compounds as claimed in any one of claims 1 to 3 wherein R¹ is H or bromine.
5. Compounds as claimed in any one of claims 1 to 4 wherein each R² is ethyl.
- 15 6. Compounds as claimed in any one of claims 1 to 5 wherein R⁴ is H or methyl.
- 20 7. Compounds as claimed in any one of claims 1 to 6 wherein R⁵ and R⁶ are each independently selected from H, chlorine, methyl or ethyl, or are taken together to form a cyclopropyl ring.
8. Compounds as claimed in any one of claims 1 to 7 wherein each of R⁷ to R¹¹ is H.
- 25 9. Compounds as claimed in any one of claims 1 to 8 wherein R¹ is at the 6-position of the naphthalene ring, as defined in formula (I).
- 30 10. A compound of formula (I) as claimed in claim 1 and as named in any one of Examples 1 to 94.
11. A process for the preparation of compounds of formula (I) and pharmaceutically acceptable derivatives thereof as defined in any of claims 1 to 10, which comprises:

39

(A), coupling a sulfonamide of formula (II)




or a protected derivative thereof with an acid chloride of formula (III)



5


or a protected derivative thereof; or

(B), coupling a sulfonamide of formula (II)



10

or a protected derivative thereof with an acid of formula (IV)



or a protected derivative thereof; or

(C), interconversion of a compound of formula (I) into another compound of formula (I); or

15

(D), deprotecting a protected derivative of compound of formula (I); and

optionally converting compounds of formula (I) prepared by any one of the processes (A) to (D) into pharmaceutically acceptable derivatives thereof.

5

12. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 10 in admixture with one or more physiologically acceptable carriers or excipients.

10

13. A compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 10 for use in human or veterinary medicine.

15

14. A method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE_2 at EP4 receptors, which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 10.

20

15. The use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 10 for the manufacture of a therapeutic agent for the treatment of a condition which is mediated by the action of PGE_2 at EP4 receptors.

25

INTERNATIONAL SEARCH REPORT

PCT/GB 01/05676

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D209/64 C07D209/66 C07D413/12 C07D405/12 C07D409/12
 C07D401/12 C07D417/12 A61K31/4035

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 25899 A (BASF AG ; MOELLER ACHIM (DE); LUBISCH WILFRIED (DE); TREIBER HANS J) 18 June 1998 (1998-06-18) abstract examples claims	1,11-15
P, A	WO 00 76969 A (WARNER LAMBERT CO ; LAI YINGJIE (US); AUGELLI SZAFRAN CORINNE ELIZA) 21 December 2000 (2000-12-21) abstract claims	1,11-15
A	US 4 395 417 A (HALL IRIS ET AL) 26 July 1983 (1983-07-26) abstract claims	1,11-15
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

20 March 2002

Date of mailing of the international search report

28/03/2002

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax. (+31-70) 340-3016

Authorized officer

Stix-Malaun, E

INTERNATIONAL SEARCH REPORT

PCT/GB 01/05676

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 014 899 A (BOWMAN ROBERT MATHEWS ET AL) 29 March 1977 (1977-03-29) abstract examples claims	1,11-15
A	US 6 030 967 A (MARUI SHOGO ET AL) 29 February 2000 (2000-02-29) abstract examples claims	1,11-15

INTERNATIONAL SEARCH REPORT

PCT/GB 01/05676

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9825899	A	18-06-1998	DE 19650975 A1	10-06-1998
			AU 742732 B2	10-01-2002
			AU 5558098 A	03-07-1998
			BG 63388 B1	31-12-2001
			BG 103399 A	31-01-2000
			BR 9713884 A	29-02-2000
			CN 1239949 A	29-12-1999
			CZ 9901743 A3	11-08-1999
			WO 9825899 A1	18-06-1998
			EP 0946509 A1	06-10-1999
			HR 970671 A1	31-10-1998
			HU 0000496 A2	28-09-2000
			JP 2001505889 T	08-05-2001
			NO 992770 A	08-06-1999
			SK 56699 A3	08-10-1999
			TR 9901282 T2	21-10-1999
			TW 420666 B	01-02-2001
			US 6172072 B1	09-01-2001
			ZA 9710979 A	18-06-1999
WO 0076969	A	21-12-2000	AU 5312000 A	02-01-2001
			NO 20015992 A	06-02-2002
			WO 0076969 A1	21-12-2000
US 4395417	A	26-07-1983	US RE32868 E	14-02-1989
US 4014899	A	29-03-1977	US 3973030 A	03-08-1976
US 6030967	A	29-02-2000	AU 3866097 A	06-03-1998
			EP 0920416 A1	09-06-1999
			WO 9807705 A1	26-02-1998
			JP 11005779 A	12-01-1999